 5. Patients must have recovered from all toxicities related to prior anticancer therapies to Grade 2 CTCAE v 4.03, provided that any concomitant medication is given prior to initiation of treatment with ceritinib. Exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment. 